 |
|
A Physician Survey on Generic Drugs and Substitution of Critical Dose Medications
Benjamin F. Banahan III, PhD;
E. M. Kolassa, PhD
Arch Intern Med. 1997;157(18):2080-2088.
Abstract
| |
Background
Generic substitution has become a common practice since the late 1970s. Because of the increased use of generic alternatives and concerns about the Food and Drug Administration standards for bioequivalency, especially with respect to narrow therapeutic index drugs, the awareness and attitudes of prescribing physicians to generic drugs and generic substitution are important.
Methods
A questionnaire designed to assess attitudes, beliefs, knowledge, and experiences with generic drugs and generic substitution was sent to 3639 physicians nationwide. Cluster analysis was used to identify attitudinal groups that were then analyzed with respect to differences in beliefs, knowledge, and experience with generic drugs. Perceptions of the therapeutic index for 15 branded drugs and comfort in substituting those products with generic alternatives were assessed.
Results
Physicians were classified into prosubstitution and antisubstitution groups, with a further division of antisubstitution physicians according to whether they felt influenced by outside pressures to substitute. Significant differences were found between the prosubstitution and antisubstitution groups with respect to beliefs about and experiences with generics and knowledge of the Food and Drug Administration bioequivalency standards. Of particular significance was the low percentage (17%) of physicians who correctly identified the Food and Drug Administration standards for bioequivalency. Prosubstitution physicians generally rated therapeutic indexes as wider than antisubstitution physicians. Physicians in all groups identified similar products they believed were not appropriate for substitution.
Conclusions
Attitudes toward generic substitution are related to prescribing behaviors, beliefs about and experience with generic substitution, and perceptions of therapeutic index and comfort with substitution. Physicians need to understand the issues surrounding generic substitution and remain empowered to influence decisions to substitute.
Arch Intern Med. 1997;157:2080-2088
Author Affiliations
From the Research Institute of Pharmaceutical Sciences and School of Pharmacy, University of Mississippi, University (Dr Banahan), and Strategic Pricing Group Inc, Framingham, Mass (Dr Kolassa).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Physician Use of Brand Versus Generic Drug Names in 1993-1994 and 2003-2004
Kwo et al.
The Annals of Pharmacotherapy 2009;43:459-468.
ABSTRACT
| FULL TEXT
Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures
Berg et al.
Neurology 2008;71:525-530.
ABSTRACT
| FULL TEXT
Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending
Kesselheim et al.
Health Aff (Millwood) 2006;25:1637-1647.
ABSTRACT
| FULL TEXT
Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000
Haas et al.
ANN INTERN MED 2005;142:891-897.
ABSTRACT
| FULL TEXT
Is it Rational, Reasonable or Excessive, and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias
Reiffel
J CARDIOVASC PHARMACOL THER 2001;6:333-339.
Generic Substitution and Optimal Patient Care
Murphy
Arch Intern Med 1999;159:429-433.
FULL TEXT
|
